News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Multiple Myeloma Research Consortium and Synta Pharmaceuticals Announce Initiation of Ganetespib Clinical Trial in Multiple Myeloma


4/10/2012 10:18:07 AM

NORWALK, Conn. & LEXINGTON, Mass.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals (NASDAQ: SNTA), as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADEĀ®) for the treatment of relapsed multiple myeloma.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES